Wells Fargo & Company MN Buys 29,738 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Wells Fargo & Company MN increased its stake in OPKO Health, Inc. (NASDAQ:OPK) by 14.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 229,262 shares of the biotechnology company’s stock after buying an additional 29,738 shares during the quarter. Wells Fargo & Company MN’s holdings in OPKO Health were worth $337,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. ExodusPoint Capital Management LP bought a new stake in OPKO Health during the fourth quarter worth $255,000. Norges Bank acquired a new position in shares of OPKO Health during the 4th quarter worth about $1,657,000. KLP Kapitalforvaltning AS bought a new stake in shares of OPKO Health in the 4th quarter valued at about $109,000. Tejara Capital Ltd lifted its stake in OPKO Health by 11.3% in the 4th quarter. Tejara Capital Ltd now owns 1,225,650 shares of the biotechnology company’s stock valued at $1,802,000 after purchasing an additional 124,524 shares during the last quarter. Finally, Cibc World Markets Corp bought a new position in OPKO Health during the fourth quarter worth about $45,000. 64.63% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on OPK shares. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Thursday, May 1st. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of OPKO Health in a report on Monday, April 7th. JPMorgan Chase & Co. started coverage on shares of OPKO Health in a report on Friday, April 25th. They issued a “neutral” rating on the stock. Finally, StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Monday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $2.75.

OPKO Health Stock Performance

OPK opened at $1.36 on Tuesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The company has a market capitalization of $913.31 million, a PE ratio of -7.16 and a beta of 1.42. The business has a fifty day simple moving average of $1.61 and a 200 day simple moving average of $1.57. OPKO Health, Inc. has a 1 year low of $1.15 and a 1 year high of $2.04.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. During the same quarter last year, the company posted ($0.12) earnings per share. The company’s revenue was down 13.7% on a year-over-year basis. Research analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current year.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock in a transaction dated Thursday, April 10th. The shares were bought at an average cost of $1.36 per share, with a total value of $170,000.00. Following the acquisition, the chief executive officer now owns 214,001,448 shares in the company, valued at $291,041,969.28. This trade represents a 0.06 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last ninety days, insiders have acquired 767,434 shares of company stock valued at $1,238,312. 49.69% of the stock is currently owned by company insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.